Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
PFE

PFE - Pfizer Inc Stock Price, Fair Value and News

27.41USD+0.43 (+1.59%)Market Closed

Market Summary

PFE
USD27.41+0.43
Market Closed
1.59%

PFE Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)

PFE Stock Price

View Fullscreen

PFE RSI Chart

PFE Valuation

Market Cap

155.3B

Price/Earnings (Trailing)

133.67

Price/Sales (Trailing)

4.43

EV/EBITDA

31.03

Price/Free Cashflow

30.42

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

-5.11%

Return on Equity

1.26%

Return on Assets

0.53%

Free Cashflow Yield

3.29%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

35.0B

Rev. Growth (Yr)

-19.51%

Rev. Growth (Qtr)

333.28%

PFE Earnings

Earnings (TTM)

1.2B

Earnings Growth (Yr)

-43.8%

Earnings Growth (Qtr)

6.5K%

Breaking Down PFE Revenue

Last 7 days

-2.2%

Last 30 days

-4.3%

Last 90 days

-1.0%

Trailing 12 Months

-31.5%

How does PFE drawdown profile look like?

PFE Financial Health

Current Ratio

1.05

Debt/Equity

0.66

Debt/Cashflow

0.14

PFE Investor Care

Dividend Yield

6.02%

Dividend/Share (TTM)

1.65

Shares Dilution (1Y)

0.38%

Diluted EPS (TTM)

-0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202435.0B000
202347.6B47.9B38.5B38.6B
202249.9B34.2B32.8B32.6B
202146.1B55.1B68.9B60.9B
202037.9B34.5B32.1B41.7B
201941.0B40.8B40.2B40.9B
201852.7B53.2B53.4B40.8B
201752.6B52.3B52.5B52.5B
201651.0B52.3B53.2B52.8B
201549.1B48.2B47.9B48.9B
201450.5B50.3B50.0B49.6B
201352.7B51.7B51.4B51.6B
201259.7B57.1B53.5B55.2B
201165.1B64.4B65.1B61.3B
201055.0B61.1B65.5B65.2B
200947.3B46.2B45.8B49.3B
2008048.4B48.3B48.3B
200700048.4B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Pfizer Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 31, 2024
denton david m
sold (taxes)
-346,987
28.66
-12,107
chief financial officer & evp
Feb 28, 2024
boshoff christoffel
sold (taxes)
-112,216
27.04
-4,150
executive vice president
Feb 28, 2024
dolsten mikael
sold (taxes)
-579,656
27.04
-21,437
president r&d
Feb 28, 2024
boshoff christoffel
acquired
-
-
11,510
executive vice president
Feb 27, 2024
damico jennifer b.
acquired
-
-
5,113
svp & controller
Feb 27, 2024
de germay alexandre
acquired
-
-
74,377
executive vice president
Feb 26, 2024
mcdermott michael
sold (taxes)
-164,792
27.18
-6,063
executive vice president
Feb 25, 2024
boshoff christoffel
sold (taxes)
-172,029
27.76
-6,197
executive vice president
Feb 25, 2024
boshoff christoffel
acquired
-
-
15,455
executive vice president
Feb 25, 2024
mcdermott michael
sold (taxes)
-83,057
27.76
-2,992
executive vice president

1–10 of 50

Which funds bought or sold PFE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 17, 2024
TruNorth Capital Management, LLC
new
-
75,647
75,647
0.03%
Jun 17, 2024
CHELSEA COUNSEL CO
reduced
-0.29
-31,216
771,450
0.44%
Jun 14, 2024
Breakwater Investment Management
new
-
5,384
5,384
-%
Jun 13, 2024
IMS Capital Management
added
3.34
-11,295
2,855,740
1.33%
Jun 13, 2024
MOSAIC FAMILY WEALTH PARTNERS, LLC
reduced
-0.41
-29,212
699,585
0.12%
Jun 13, 2024
KEYNOTE FINANCIAL SERVICES LLC
new
-
1,765,260
1,765,260
1.48%
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
39.38
128,783
664,722
0.05%
Jun 10, 2024
Hamilton Wealth, LLC
reduced
-91.74
-6,562,170
567,936
0.18%
Jun 04, 2024
Tactive Advisors, LLC
new
-
370,157
370,157
0.20%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-9.55
-29,978,000
205,266,000
0.38%

1–10 of 50

Are Funds Buying or Selling PFE?

Are funds buying PFE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PFE
No. of Funds

Unveiling Pfizer Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.97%
506,479,807
SC 13G/A
Jan 29, 2024
state street corp
5.10%
287,875,814
SC 13G/A
Jan 26, 2024
blackrock inc.
7.7%
434,748,255
SC 13G/A
Feb 09, 2023
vanguard group inc
8.94%
501,636,220
SC 13G/A
Feb 07, 2023
state street corp
5.08%
284,943,697
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
442,868,761
SC 13G/A
Feb 14, 2022
state street corp
5.09%
285,771,591
SC 13G/A
Feb 10, 2022
vanguard group inc
8.29%
465,274,925
SC 13G/A
Feb 01, 2022
blackrock inc.
7.3%
409,985,645
SC 13G/A
Feb 12, 2021
state street corp
5.03%
279,831,373
SC 13G

Recent SEC filings of Pfizer Inc

View All Filings
Date Filed Form Type Document
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 11, 2024
11-K
Employee Benefit Details
Jun 11, 2024
11-K
Employee Benefit Details
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
May 31, 2024
SD
SD
May 22, 2024
8-K
Current Report
May 16, 2024
4
Insider Trading

Peers (Alternatives to Pfizer Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.5B
85.6B
-5.78% -11.28%
9.11
4.09
5.68% 202.39%
324.2B
61.4B
-2.40% 17.12%
140.58
5.28
6.11% -82.30%
164.1B
29.5B
-2.07% 33.24%
43.62
5.56
12.76% -52.47%
155.3B
35.0B
-4.26% -31.55%
133.67
4.43
-26.40% -92.03%
78.7B
27.4B
-6.75% -19.92%
162.39
2.87
1.51% -91.32%
19.1B
16.0B
4.36% 125.46%
-38.63
1.19
7.23% 71.10%
MID-CAP
4.1B
1.7B
1.12% -24.14%
9.51
2.39
54.01% 364.56%
3.5B
4.6B
-14.38% -25.76%
-452.34
0.76
-0.06% 94.55%
2.4B
9.0B
-4.43% -11.97%
-5.22
0.26
10.01% -27.45%
2.0B
676.2M
-7.89% -27.22%
12.66
2.9
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-14.65% 8.33%
-3.72
1.76
24.65% 80.36%
21.5M
1.3M
-16.22% -51.69%
-2.9
16.47
-98.14% -104.71%
13.3M
89.6M
-27.78% -33.90%
-0.93
0.19
287.27% -129.41%
2.3M
21.5M
-10.53% -89.57%
-0.3
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Pfizer Inc News

Latest updates
MarketWatch27 hours ago
Investor's Business Daily12 Jun 202404:57 pm
Forbes07 May 202407:00 am

Pfizer Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue333.3%14,8793,43413,2323,49018,4863,26122,6383,2193,5263,42024,03518,89914,51611,42710,2779,86410,0831,84312,68013,26413,118
  S&GA Expenses-23.6%3,4954,5753,2813,4973,4184,6453,3913,0482,5934,1042,8992,9232,7773,7392,6582,6592,5412,6163,2603,5113,339
EBITDA Margin-19.7%0.20*0.25*0.76*0.91*1.17*1.26*1.22*1.13*0.69*0.51*0.43*0.40*---------
Interest Expenses-60.9%4151,062332402419321350318453262407353445344387438472341437424385
Income Taxes-91.4%2933,420-964-71.007152303561,5701,172249-3281,123808-64.00-347422359-1,9823,047-915433
Earnings Before Taxes182.9%3,421-4,129-3,3522,2696,2705,2319,00111,4479,0503,8277,8436,9495,6925985703,0262,842-7,86910,7274,1414,323
EBT Margin-286.7%-0.05*0.03*0.44*0.69*0.98*1.06*1.02*0.94*0.55*0.40*0.31*0.25*---------
Net Income6527.7%3,11547.00-2,3823825,5432118,6082104685788,1463304612211,46951840537.001485,0463,884
Net Income Margin-64.3%0.03*0.09*-0.06*0.29*0.29*0.29*0.30*0.27*0.19*0.16*0.13*0.05*---------
Free Cashflow-90.8%3864,1962,646-2,12273.007,5815,1337,4195,8984,91210,21110,762---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.4%221,095226,50142,830220,168196,000197,00041,137195,000184,000181,47646,335169,920158,818154,22944,97544,24445,840167,59446,081156,199155,000
  Current Assets-2.1%42,41543,3335,87673,34750,07851,2595,93267,46654,42059,6936,89048,81439,53335,0676,6147,1368,21332,8037,50547,07345,290
    Cash Equivalents-74.8%7192,8533,1482,6322,2224681,3381,8242,5131,9832,0342,4181,8091,8251,6271,8452,1961,3502,8461,8372,018
  Inventory6.9%10,89210,18910,20410,3109,5418,9819,51310,4549,9799,0598,6408,9488,4938,0209,2958,5648,4237,0688,2228,2338,029
  Net PPE-0.7%18,80318,94017,86217,48817,05216,27415,44115,24415,10914,88214,43614,22414,01113,74514,40314,11314,04012,96913,70113,52113,467
  Goodwill2.2%69,29767,78351,52751,57251,47651,37582349,89150,21149,20849,48949,86749,79149,55659,90258,44958,50248,18158,66553,35253,487
Liabilities-6.3%128,537137,21321,862120,87594,381101,28822,455107,821101,155104,01310,35199,60589,95390,75610,57610,18710,677104,14810,77696,27496,263
  Current Liabilities-15.3%40,49747,7946,11734,64736,56242,1385,23547,41039,26842,6715,13335,66426,65225,9205,2464,9925,52437,3045,24132,03029,423
  Long Term Debt-0.4%61,30761,53861,04861,35631,70433,00032,62934,29435,65636,00036,25035,35435,34737,13349,78550,52936,28135,95536,04436,16835,733
    LT Debt, Current-55.6%1,0012,2542,2603,5653,5672,5602,5661,2762601,6362,6633,6873,6762,0022,1491,4813371,4622,4312,1394,471
    LT Debt, Non Current-0.4%61,30761,53861,04861,35631,70433,00032,62934,29435,65636,00036,25035,35435,34737,13349,78550,52936,28135,95536,04436,16835,733
Shareholder's Equity3.7%92,28289,01420,71999,293101,23695,91618,45587,46982,68577,46235,70570,31568,86563,47334,15464,57065,34163,44735,19959,92459,158
  Retained Earnings2.5%121,318118,353126,411128,796131,102125,656122,967116,608111,193103,394102,25296,34695,15890,392100,284100,203101,00097,670100,11394,44093,388
  Additional Paid-In Capital0.4%92,99792,63192,49692,32992,15391,80291,35991,18390,84490,59189,97389,33689,00288,67488,16187,88687,68087,42887,09986,96386,635
Accumulated Depreciation2.0%16,36216,04515,77915,55415,51415,17414,93114,96915,35815,07415,40315,32815,10514,81216,63616,88916,92916,78916,72816,38916,158
Shares Outstanding0.2%5,6575,6435,6465,6465,6345,6085,6065,6055,6175,6015,6095,591---------
Minority Interest0.7%276274249274266256227261261262279273245235245138133303105357352
Float----207,000---294,000---223,000---169,000---241,000-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-79.2%1,0905,2403,456-1,2081,2128,5825,9748,1706,5415,91410,82911,2994,5385,6252,0903,5553,1333,7694,5102,6111,698
  Share Based Compensation81.8%22012115114810536413528786.0049629322117228722418757.0023964.00199185
Cashflow From Investing115.8%1,732-10,996888-25,4853,315-4,410-627-11,313567-2,586-10,076-8,137-1,7478,330481-13,011-71.00-2,833-6,760-1,9027,550
Cashflow From Financing-190.6%-4,9315,442-3,77927,174-2,771-5,015-5,7612,520-6,578-3,351-1,101-2,557-2,807-13,787-2,8219,159-2,200-2,4403,273-851-8,467
  Buy Backs---------2,000-----------8,865
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PFE Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Apr. 02, 2023
Alliance revenues[1]$ 2,172$ 2,060
Total revenues14,87918,486
Costs and expenses:  
Cost of sales[2]3,3794,886
Selling, informational and administrative expenses[2]3,4953,418
Research and development expenses[2]2,4932,505
Acquired in-process research and development expenses021
Amortization of intangible assets1,3081,103
Restructuring charges and certain acquisition-related costs1029
Other (income)/deductions––net680275
Income from continuing operations before provision/(benefit) for taxes on income[3]3,4216,270
Provision/(benefit) for taxes on income293715
Income from continuing operations3,1285,555
Discontinued operations––net of tax(5)1
Net income before allocation to noncontrolling interests3,1235,556
Less: Net income attributable to noncontrolling interests813
Net income attributable to Pfizer Inc. common shareholders$ 3,115$ 5,543
Earnings per common share––basic:  
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)$ 0.55$ 0.98
Discontinued operations––net of tax (in dollars per share)00
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)0.550.98
Earnings per common share––diluted:  
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)0.550.97
Discontinued operations––net of tax (in dollars per share)00
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)$ 0.55$ 0.97
Weighted-average shares--basic (in shares)5,6575,634
Weighted-average shares--diluted (in shares)5,6975,727
Product revenues  
Revenues[1]$ 12,443$ 16,221
Royalty revenues  
Revenues[1]$ 263$ 204
[1]See Note 1A.
[2]Exclusive of amortization of intangible assets.
[3]Income from continuing operations before provision/(benefit) for taxes on income. As described above, in connection with the organizational changes effective in the first quarter of 2024, costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations and overhead costs associated with our manufacturing operations are now included in Biopharma’s earnings. We have reclassified $1.4 billion of net costs in the first quarter of 2023 from Other business activities to Biopharma to conform to the current period presentation.

PFE Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Assets  
Cash and cash equivalents$ 719$ 2,853
Short-term investments11,2099,837
Trade accounts receivable, less allowance for doubtful accounts: 2024—$479; 2023—$47010,98911,566
Inventories[1]10,89210,189
Current tax assets4,2333,978
Other current assets4,3724,911
Total current assets42,41543,333
Equity-method investments8,12311,637
Long-term investments3,4903,731
Property, plant and equipment, less accumulated depreciation: 2024—$16,362; 2023—$16,04518,80318,940
Identifiable intangible assets[2]62,82964,900
Goodwill[3]69,29767,783
Noncurrent deferred tax assets and other noncurrent tax assets4,9423,706
Other noncurrent assets11,19712,471
Total assets221,095226,501
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2024—$1,001; 2023—$2,2548,23210,350
Trade accounts payable5,5916,710
Dividends payable02,372
Income taxes payable3,1922,349
Accrued compensation and related items2,1922,776
Deferred revenues2,5022,700
Other current liabilities18,78820,537
Total current liabilities40,49747,794
Long-term debt61,30761,538
Pension and postretirement benefit obligations2,0762,167
Noncurrent deferred tax liabilities931640
Other taxes payable8,6038,534
Other noncurrent liabilities15,12216,539
Total liabilities128,537137,213
Commitments and Contingencies
Common stock480478
Additional paid-in capital92,99792,631
Treasury stock(114,755)(114,487)
Retained earnings121,318118,353
Accumulated other comprehensive loss(7,758)(7,961)
Total Pfizer Inc. shareholders’ equity92,28289,014
Equity attributable to noncontrolling interests276274
Total equity92,55889,288
Total liabilities and equity$ 221,095$ 226,501
[1]The increase from December 31, 2023 reflects higher inventory levels for certain products mainly for supply recovery and network strategy, partially offset by decreases due to net market demand.
[2]The decrease is primarily due to amortization expense of $1.3 billion and measurement period adjustments related to our acquisition of Seagen of $660 million (see Note 2A).
[3]All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 13A), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.
PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
 CEO
 WEBSITEpfizer.com
 INDUSTRYPharmaceuticals
 EMPLOYEES65535

Pfizer Inc Frequently Asked Questions


What is the ticker symbol for Pfizer Inc? What does PFE stand for in stocks?

PFE is the stock ticker symbol of Pfizer Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pfizer Inc (PFE)?

As of Tue Jun 18 2024, market cap of Pfizer Inc is 155.38 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers. The fair value of Pfizer Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pfizer Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PFE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pfizer Inc a good stock to buy?

The fair value guage provides a quick view whether PFE is over valued or under valued. Whether Pfizer Inc is cheap or expensive depends on the assumptions which impact Pfizer Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PFE.

What is Pfizer Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, PFE's PE ratio (Price to Earnings) is 133.72 and Price to Sales (PS) ratio is 4.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PFE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pfizer Inc's stock?

In the past 10 years, Pfizer Inc has provided 0.023 (multiply by 100 for percentage) rate of return.